| NCT ID | NCT01571986 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Università Vita-Salute San Raffaele |
| Condition | Acute Respiratory Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 750 participants |
| Start Date | 2012-02 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 750 participants in total. It began in 2012-02 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A single center, observational, prospective study to improve knowledge about non-invasive ventilation, obtaining data about compliance, efficacy, imaging in patients who already receive non-invasive ventilation as standard of care.
Eligibility Criteria
Inclusion Criteria: * treatment with non-invasive ventilation * informed consent Exclusion Criteria: * refusal of informed consent
Contact & Investigator
Luca Cabrini, MD
✉ cabrini.luca@hsr.itFrequently Asked Questions
Who can join the NCT01571986 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Acute Respiratory Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01571986 currently recruiting?
Yes, NCT01571986 is actively recruiting participants. Contact the research team at cabrini.luca@hsr.it for enrollment information.
Where is the NCT01571986 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT01571986 clinical trial?
NCT01571986 is sponsored by Università Vita-Salute San Raffaele. The trial plans to enroll 750 participants.